Research Papers

25 of 43 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice.
Liu J; Cang T; Jiang C; Li K; Liu S; Wang H; Wang M; Chen Y; Shao Y; Liu J.
Future Virol (Unknown)
Published: 2023
2/6 Transparent
Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19.
Horga A; Kuritzkes DR; Kowalczyk JJ; Pietropaolo K; Belanger B; Lin K; Perkins K; Hammond J.
Future Virol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins.
Alanzi AR; Parvez MK; Al-Dosari MS.
Future Virol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Antiviral attributes of bee venom as a possible therapeutic approach against SARS-CoV-2 infection.
Goswami S; Chowdhury JP.
Future Virol (Unknown)
Published: 2023
2/6 Transparent
Validation of a risk prediction model for COVID-19: the PERIL prospective cohort study.
Mohammedain SA; Badran S; Elzouki AY; Salim H; Chalaby A; Siddiqui M; Hussein YY; Rahim HA; Thalib L; Alam MF; Al-Badriyeh D; Al-Maadeed S; Doi SA.
Future Virol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).
Horga A; Saenz R; Yilmaz G; Simón-Campos A; Pietropaolo K; Stubbings WJ; Collinson N; Ishak L; Zrinscak B; Belanger B; Granier C; Lin K; C Hurt A; Zhou XJ; Wildum S; Hammond J.
Future Virol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
Targeting host calcium channels and viroporins: a promising strategy for SARS-CoV-2 therapy.
Fani M; Moossavi M; Bakhshi H; Jahrodi AN; Khazdair MR; Zardast AH; Ghafari S.
Future Virol (Unknown)
Published: 2023
2/6 Transparent
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes.
Nag S; Mandal S; Mukherjee O; Mukherjee S; Kundu R.
Future Virol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Natural killer cells in COVID-19: from infection, to vaccination and therapy.
Zafarani A; Razizadeh MH; Pashangzadeh S; Amirzargar MR; Taghavi-Farahabadi M; Mahmoudi M.
Future Virol (Unknown)
Published: 2023
2/6 Transparent
SARS-CoV-2 RNA-dependent RNA polymerase as a target for high-throughput drug screening.
Wu J; Chen Z; Han X; Chen Q; Wang Y; Feng T.
Future Virol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Variation analysis of SARS-CoV-2 complete sequences from Iran.
Moradi J; Moradi P; Alvandi AH; Abiri R; Moghoofei M.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
Relevance of cycle threshold values in mass screening by reverse-transcription-PCR during COVID-19 pandemic in Belgium:…
Dufour P; Paridaens H; Senterre JM; Minon JM.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
Digging for the discovery of SARS-CoV-2 nsp12 inhibitors: a pharmacophore-based and molecular dynamics simulation study.
Askari FS; Ebrahimi M; Parhiz J; Hassanpour M; Mohebbi A; Mirshafiey A.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations.
Solanki K; Rajpoot S; Kumar A; J Zhang KY; Ohishi T; Hirani N; Wadhonkar K; Patidar P; Pan Q; Baig MS.
Future Virol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Andrographolide induces anti-SARS-CoV-2 response through host-directed mechanism: an <i>in silico</i> study.
Das BS; Das NC; Swain SS; Mukherjee S; Bhattacharya D.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program.
Rajpal VR; Sharma S; Sehgal D; Singh A; Kumar A; Vaishnavi S; Tiwari M; Bhalla H; Goel S; Raina SN.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
Mapping of SARS-CoV-2 spike protein evolution during first and second waves of COVID-19 infections in India.
Rajpal VR; Sharma S; Kumar A; Vaishnavi S; Singh A; Sehgal D; Tiwari M; Goel S; Raina SN.
Future Virol (Unknown)
Published: 2022
3/6 Transparent
Data
Clinical course of idiopathic inflammatory myopathies in COVID-19 pandemic: a single-center experience.
Apaydin H; Erden A; Güven SC; Armağan B; Karakaş Ö; Özdemir B; Polat B; Eksin MA; Omma A; Kucuksahin O.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
Evaluation of SARS-CoV-2 genome detection by real-time PCR assay using pooled specimens.
Tavakoli F; Yavarian J; Shafiei Jandaghi NZ; Sadeghi K; Ghavami N; Salimi V; Mokhtari-Azad T.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent.
Zhang M; Gong Y; Jiao S.
Future Virol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Need for more robust research on the effectiveness of masks in preventing COVID-19 transmission.
Nie J; Kang L; Pian Y; Hu J.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
Reviewing findings on the polypeptide sequence of the SARS-CoV-2 S-protein to discuss the origins of the virus.
Cattaneo AM.
Future Virol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Can anti-parasitic drugs help control COVID-19?
Panahi Y; Dadkhah M; Talei S; Gharari Z; Asghariazar V; Abdolmaleki A; Matin S; Molaei S.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
Research progresses in vertical transmission of SARS-CoV-2 among infants born to mothers with COVID-19.
Peng Z; Zhang J; Shi Y; Yi M.
Future Virol (Unknown)
Published: 2022
2/6 Transparent
Antineutrophil cytoplasmic antibody positivity and clinical implications in COVID-19.
Güven SC; Apaydın H; Özdemir B; Armağan B; Ateş İ; Erden A; Küçükşahin O; Omma A.
Future Virol (Unknown)
Published: 2022
2/6 Transparent